SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Completed · Phase 2
Conditions studied: Endometrial Cancer
In brief
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Key facts
- Study ID
- NCT04205630
- Run by
- Byondis B.V.
- People needed
- 64
- Starts
- 2020-05-28
- Expected to finish
- 2023-04-25
- Last updated by the study team
- 2024-05-30
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may not qualify if…
- Current or previous use of a prohibited medication as listed in the protocol;
- History of infusion-related reactions and/or hypersensitivity to trastuzumab;
- History of keratitis;
- Severe, uncontrolled systemic disease at screening;
- Left Ventricular Ejection Fraction (LVEF) < 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab;
- History of clinically significant cardiovascular disease;
- Symptomatic brain metastases, brain metastases requiring steroids to manage symptoms, or treatment for brain metastases within 8 weeks prior to randomization;
- History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
Where it is running
- Smilow Cancer Hospital (Yale) — New Haven, Connecticut, United States
- MedTrials — Krakow, Poland
- St. John of Dukla Oncology Center of Lublin Land — Lublin, Poland
- Arkhangelsk Clinical Oncology Center — Arkhangelsk, Russia
- Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center — Chelyabinsk, Russia
- Regional Oncology Center — Irkutsk, Russia
- Clinical Oncology Center — Omsk, Russia
- Orenburg Regional Clinical Oncology Center — Orenburg, Russia
- Oncology Center of Moskovskiy District — Saint Petersburg, Russia
- Private Medical Institution "EVROMEDSERVIS" — Saint Petersburg, Russia
- AV Medical Group — Saint Petersburg, Russia
- Oncology Center #2 — Sochi, Russia
- Tambov Regional Oncological Clinical Center — Tambov, Russia
- Republican Clinical Oncology Center — Ufa, Russia
- Volgograd Regional Clinical Oncology Center — Volgograd, Russia
- National Cancer Research Center — Belgrade, Serbia
- Oncology Institute of Vojvodina (IOV), Clinic of Surgical Oncology, Department of Gynecology — Kamenitz, Serbia
- Clinical Center Nis, Clinic of Oncology — Niš, Serbia
- National University Hospital, Department of Hematology-Oncology — Singapore, Singapore
- National Cancer Centre Singapore — Singapore, Singapore
- Seoul National University Bundang Hospital — Seongnam-si, South Korea
- Seoul National University Hospital — Seoul, South Korea
- Severance Hospital, Yonsei University Health System — Seoul, South Korea
- Samsung Medical Center — Seoul, South Korea
- The Catholic University of Korea, Seoul St. Mary's Hospital — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.